DelMar Pharma of Vancouver and Menlo Park reported early results from its China Phase II trial of VAL-083 as a first line treatment for glioblastoma multiforme. VAL-083 is being administered along with radiation to patients with newly-diagnosed, MGMT-unmethylated GBM. Among the first 17 patients who have had three post-treatment examinations, 53% showed a complete response and 41% had stable disease. Only one of the 17 has died. The trial is being conducted in collaboration with Guangxi Wuzhou Pharma, Del Mar’s China partner. Source: China Biotoday
